{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-057696","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2021-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.440222+00:00","generated_at":"2026-06-28T06:35:20.417863+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Bolt Biotherapeutics appoints two new directors and lead independent director","bullets":["Director Peter Moldt resigned from Board and Compensation Committee; no disagreement.","Board expanded from 8 to 9; appointed Brian O'Callaghan and Frank Lee as Class I directors.","O'Callaghan named chair of Compensation Committee; Lee joins Nominating and Corporate Governance Committee.","Each new director received initial option for 27,860 shares, annual option for 13,930 shares, and cash retainers.","Existing director Jim Healy appointed as lead independent director."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-057696","json":"https://secwatch.observer/filing/0001564590-21-057696.json","markdown":"https://secwatch.observer/filing/0001564590-21-057696.md","text":"https://secwatch.observer/filing/0001564590-21-057696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/bolt-8k_20211115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:35:20.417863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2293d0a19e","claim":"Peter Moldt resigned as Director at Bolt Biotherapeutics, Inc..","evidence_excerpt":"On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6a8b579cc3","claim":"Frank Lee was appointed as Director at Bolt Biotherapeutics, Inc..","evidence_excerpt":"The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7f21883b00","claim":"Jim Healy was appointed as Lead Independent Director at Bolt Biotherapeutics, Inc..","evidence_excerpt":"the Board appointed Jim Healy, an existing member of the Board, to serve as the lead independent director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"e64faff586","claim":"Brian O'Callaghan was appointed as Director at Bolt Biotherapeutics, Inc..","evidence_excerpt":"The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}